Hollandt J H, Kuhl S, Siegert R
HNO-Klinik der Medizinischen Universität zu Lübeck.
Laryngorhinootologie. 1997 Sep;76(9):550-3. doi: 10.1055/s-2007-997477.
Nocturnal ventilation with nCPAP has been established as the safest and most efficient nonsurgical treatment for OSAS. Long-term results, however, are determined by the patients' compliance with therapy. The aim of this study was the objective measurement of long-term acceptability of nCPAP therapy in all patients receiving this treatment in our sleep laboratory between January 1990 and March 1995.
We prospectively investigated 41 patients (36 male, 5 female) with moderate to severe OSAS who received nCPAP therapy. Mean time of follow-up was 20.6 months, ranging from 1.2 to 53.5 months. Therapy was indicated when OSAS was confirmed by cardiorespiratory polygraphy and either (1) the patient complained of daytime sleepiness or (2) the patient possessed an apnea-hypopnea index greater than 30/h or when the mean oxygen desaturation was below 80% regardless of the presenting symptoms. The compliance with treatment was defined as a mean rate of use of over 5 hours per night calculated from the time counter on the nCPAP machine.
33 patients (88.5%) have continued using nCPAP until the present time but only 24 patients (59%) met our criteria for long-term acceptance and this group was identified as responders. We found no significant differences in age, body mass index, apnea-hypopnea index, and nCPAP-pressure between responders and non-responders.
Although nCPAP is the safest treatment for OSAS, there is still a large group of patients with moderate to severe OSAS who are not efficiently treated with nCPAP because of the low long-term acceptability of this therapy. With respect to this group of patients, surgical approaches have to be considered as an alternative therapy.
无创持续气道正压通气(nCPAP)夜间通气已被确立为阻塞性睡眠呼吸暂停低通气综合征(OSAS)最安全、最有效的非手术治疗方法。然而,长期治疗效果取决于患者对治疗的依从性。本研究的目的是客观测量1990年1月至1995年3月在我们睡眠实验室接受该治疗的所有患者对nCPAP治疗的长期可接受性。
我们前瞻性地研究了41例接受nCPAP治疗的中重度OSAS患者(36例男性,5例女性)。平均随访时间为20.6个月,范围从1.2个月至53.5个月。当通过心肺多导睡眠图确诊为OSAS,且满足以下条件之一时开始治疗:(1)患者主诉白天嗜睡;(2)患者呼吸暂停低通气指数大于30次/小时;或无论有无症状,平均氧饱和度低于80%。治疗依从性定义为根据nCPAP机器上的时间计数器计算出的每晚平均使用时间超过5小时。
33例患者(88.5%)至今仍在使用nCPAP,但只有24例患者(59%)符合我们的长期接受标准,这组患者被确定为有反应者。我们发现有反应者和无反应者在年龄、体重指数、呼吸暂停低通气指数和nCPAP压力方面没有显著差异。
尽管nCPAP是治疗OSAS最安全的方法,但仍有一大组中重度OSAS患者因该疗法长期可接受性低而未得到有效治疗。对于这组患者,必须考虑手术方法作为替代治疗。